Modulation of B-cell tolerance by coreceptor molecules
Project Number7R21AI059833-02
Former Number5R21AI059833-02
Contact PI/Project LeaderRICKERT, ROBERT C
Awardee OrganizationSANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Description
Abstract Text
DESCRIPTION (provided by applicant): Induction of autoimmunity by infection and inflammation has been suggested in connection with a number of diseases and has been supported by demonstrations of cross-reactivity of certain self- and microbial antigens. It is noteworthy that B-lymphocytes are critical antigen presenting cells in the development of diabetes, arthritis and lupus in model systems. In this application, we seek to establish complement C3d generation as a predisposing factor for B cell-dependent autoimmune disease. Notably, C3d is deposited in the kidney and excreted in the urine during the advanced symptoms of renal disease. In this application, we will test the hypothesis that C3d is not only correlative, but can be causative of arthritis or a lupus-like disease when bound to the inducing self-antigen. This hypothesis will be examined in the type II collagen (CII)- and the glucose-6-phosphate isomerase (GPI)-induced models of arthritis by coupling C3d to CII or GPI and determining the potential of these C3d-bound self-antigens to induce disease. A similar approach will be used to form immunoconjugates of the Sm ribonucleoprotein and C3d to create a model of systemic lupus erythematosus (SLE). C3d-bound antigens promote B cell activation by binding the B cell receptor and CD21, which signals via CD19. CD19 has also been implicated as a target for negative regulation by Fc-gammaRIIB when co-engaged by immune complexes. To understand how CD21 binding may lead to a breach in B cell tolerance, experiments are proposed to address the role of CD21 in central tolerance of newly formed B cells. Moreover, we will investigate the issue of signal integration by the co-receptors as applied to the physiologic context of immune complexes and C3d-bound antigen co-engaging CD19/CD21/CD32 and the BCR. Completion of this R21 will lay the foundation for future studies defining the molecular basis of C3d/CD21 adjuvant potential in autoimmune disease, with the prospect of designing reagents to block CD21 function in some contexts to ameliorate disease.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
B cell receptorB lymphocyteCD antigensCD19 moleculearthritisautoantigensautoimmune disorderbiological signal transductioncomplementcomplement receptordisease /disorder etiologyenzyme linked immunosorbent assaygenetically modified animalsimmune compleximmune tolerance /unresponsivenessimmunocytochemistryimmunoregulationlaboratory mouseleukocyte activation /transformationprotein protein interactionreceptor bindingsystemic lupus erythematosustissue /cell culture
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
020520466
UEI
PHMKYKKJLQS1
Project Start Date
01-April-2004
Project End Date
31-March-2006
Budget Start Date
01-April-2005
Budget End Date
31-March-2006
Project Funding Information for 2005
Total Funding
$238,750
Direct Costs
$125,000
Indirect Costs
$113,750
Year
Funding IC
FY Total Cost by IC
2005
National Institute of Allergy and Infectious Diseases
$238,750
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7R21AI059833-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7R21AI059833-02
Patents
No Patents information available for 7R21AI059833-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7R21AI059833-02
Clinical Studies
No Clinical Studies information available for 7R21AI059833-02
News and More
Related News Releases
No news release information available for 7R21AI059833-02
History
No Historical information available for 7R21AI059833-02
Similar Projects
No Similar Projects information available for 7R21AI059833-02